Faculty of Pharmacy Dean’s Award goes to Sandoz Development Center Slovenia associate Klemen Naveršnik, PhD.
Yesterday, during the ceremony to mark the Research Day of the Faculty of Pharmacy held as part of University Ljubljana Week, the recognitions were presented to students as well as the Dean’s and Prešeren Awards of the Faculty of Pharmacy. Klemen Naveršnik, PhD., prototype analytics group head at the Sandoz Development Center Slovenia, received the Dean’s award for the most prominent scientific achievement in 2014.
The award was received for that part of his doctoral thesis titled The role of correlations in pharmacoeconomic models. The chapter, Measuring the cost-effectiveness during routine use: proposal for risk-sharing in the introduction of online e-service for the treatment of depression, was published in a high-impact scientific journal, which is a prerequisite for receiving the Dean’s Award.
»I researched economic evaluation of the e-service for the treatment of depression. My colleagues from the University of Primorska have developed a program for support treatment of depression, based on the use of on-line and mobile communication channels. I have then developed an economic model to evaluate the cost-effectiveness of this service. The service proved to be highly cost-effective. Unfortunately, the result is fairly uncertain due to a lack of data on the effectiveness of the service in real life. Therefore I used a model of risk-sharing between the payer and the service provider that enables us to provide a high value service for the patient. It’s all about the regulation of service price for each patient with regard to real performance achieved, i.e. a kind of efficacy guarantee,« explained Klemen Naveršnik.
All five recipients of this year’s Dean’s Awards presented their work in a lecture accompanying the Faculty of Pharmacy Research Day. »It was a great opportunity for me to present my work at the Faculty of Pharmacy Research Day, since not many researchers deal with economic evaluation of the health care system. This topic certainly attracted a lot of attention as was evident from the number of questions put forward by the audience and the lively discussion that followed the presentation. Health system economics is highly developed around the world but in Slovenia the number of competent interlocutors in this area is relatively small. This prize will, I hope, at least to a small extent, contribute to raising the interest of the professional public in this matter,« added Klemen Naveršnik.
Lek, a Sandoz company, is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/en.
Sandoz, the generic pharmaceuticals division of Novartis, is a global leader in the generic pharmaceutical sector. Sandoz employs over 26,500 employees and its products are available in more than 160 countries, offering a broad range of high-quality, affordable products that are no longer protected by patents. With USD 9.2 billion in sales in 2013, Sandoz has a portfolio of approximately 1,100 molecules, and holds the #1 position globally in biosimilars as well as in generic injectables, ophthalmics, dermatology and antibiotics, complemented by leading positions in the cardiovascular, metabolism, central nervous system, pain, gastrointestinal, respiratory, and hormonal therapeutic areas. Sandoz develops, produces, and markets these medicines, as well as active pharmaceutical and biotechnological substances. Nearly half of Sandoz’s portfolio is in differentiated products, which are defined as products that are more difficult to scientifically develop and manufacture than standard generics.
In addition to strong organic growth since consolidating its generics businesses under the Sandoz brand name in 2003, Sandoz has benefitted from strong growth of its acquisitions, which include Lek (Slovenia), Sabex (Canada), Hexal (Germany), Eon Labs (US), EBEWE Pharma (Austria), Oriel Therapeutics (US), and Fougera Pharmaceuticals (US).
Sandoz is on Twitter. Sign up to follow @Sandoz_global at http://twitter.com/Sandoz_Global.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit www.novartis.com.
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32